References
- Alberts DS, Griffith KS, Goodman GE, Herman TS, Murray E. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother Pharmacol 1980; 5: 11–15.
- Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (((2-[(2-hydroxyethyl)amino]ethyl) amino)) -9,10-anthracene-dione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 1980; 40: 1516-1518.
- Edan G, Morrissey S, Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35–39.
- Hande KR. Clinical applications of anticancer drugs tar-geted to topoisomerase II. Biochim Biophys Acta 1998; 1400: 173–184.
- Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48–58.
- Lage H. ABC-transporters: implications on drug resis-tance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22: 188–199.
- Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468–7485.
- Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537–7552.
- Lage H, Dietel M. Effect of the breast cancer resistance protein on atypical multidrug resistance. Lancet Oncol 2000; 1: 169–175.
- Kellen JA. The reversal of multidrug resistance: an update. J Exp Ther Oncol 2003; 3: 5–13.
- Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003; 46: 4805–4817.
- Thomas H, Coley HM. Overcoming multidrug resis-tance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159–165.
- Davies PJ, Willecke K. Segregation of human hypoxan-thine phosphoribosyltransferase activity from somatic cell hybrids isolated after fusion of mouse gene transfer cells with Chinese hamster cells. Mol Gen Genet 1977; 154: 191–197.
- Willecke K, Klomfass M, Mierau R, Dohmer J. Interspecies transfer via total cellular DNA of the gene for hypoxanthine phosphoribosyltransferase into cultured mouse cells. Mol Gen Genet 1979; 170: 179–185.
- Puck TT, Cieciura SJ, Robinson A. Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J Exp Med 1958; 108: 945–956.
- Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FESS Lett 2003; 545: 144–150.
- Wichert A, Stege A, Midorikawa Y, Holm PS, Lage H. Glypican-3 is involved in cellular protection against mitox-antrone in gastric carcinoma cells. Oncogene 2004; 23: 945–955.
- Skehan P, Storeng R, Scudiero D, et al. New colon-metric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107–1112.
- Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated mul-tidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 2004; 11: 699–706.
- Lage H, Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 2002; 128: 349–357.
- Roos G. Mitoxantrone sensitivity of human hematopoi-etic cell lines. Leuk Res 1987; 11: 519–524.
- Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 1986; 232: 643–645.
- Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR1 gene activation. J Clin Invest 1997; 99: 1947-1957.
- Knutsen T, Mickley LA, Ried T, et al. Cytogenetic and molecular characterization of random chromosomal rearrange-ments activating the drug resistance gene MDR1/P-glycopro-tein in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998; 23: 44–45.